Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial

Our aim was to examine the association of pre-treatment tumor infiltrating lymphocyte (TIL) count and PD-L1 levels with pathologic complete response (pCR) and assess immune marker changes following treatment in tumor specimens from the S0800 clinical trial which randomized patients to bevacizumab+na...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer Ther
Autors principals: Pelekanou, Vasiliki, Barlow, William E., Nahleh, Zeina A., Wasserman, Brad, Lo, Ying-Chun, von Wahlde, Marie-Kristin, Hayes, Daniel, Hortobagyi, Gabriel N., Gralow, Julie, Tripathy, Debu, Porter, Peggy, Szekely, Borbala, Hatzis, Christos, Rimm, David L., Pusztai, Lajos
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6548451/
https://ncbi.nlm.nih.gov/pubmed/29588392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-1005
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars